JP2019514950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514950A5 JP2019514950A5 JP2018557418A JP2018557418A JP2019514950A5 JP 2019514950 A5 JP2019514950 A5 JP 2019514950A5 JP 2018557418 A JP2018557418 A JP 2018557418A JP 2018557418 A JP2018557418 A JP 2018557418A JP 2019514950 A5 JP2019514950 A5 JP 2019514950A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- optionally substituted
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330350P | 2016-05-02 | 2016-05-02 | |
| US62/330,350 | 2016-05-02 | ||
| PCT/US2017/030577 WO2017192543A1 (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514950A JP2019514950A (ja) | 2019-06-06 |
| JP2019514950A5 true JP2019514950A5 (enExample) | 2020-06-18 |
| JP6991585B2 JP6991585B2 (ja) | 2022-01-12 |
Family
ID=58699299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557418A Expired - Fee Related JP6991585B2 (ja) | 2016-05-02 | 2017-05-02 | メニン阻害剤としてのピペリジン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10899738B2 (enExample) |
| EP (1) | EP3452461B1 (enExample) |
| JP (1) | JP6991585B2 (enExample) |
| KR (1) | KR20190015275A (enExample) |
| CN (1) | CN109415337B (enExample) |
| AU (1) | AU2017259436B2 (enExample) |
| BR (1) | BR112018072570A2 (enExample) |
| CA (1) | CA3022868A1 (enExample) |
| ES (1) | ES2899936T3 (enExample) |
| IL (2) | IL262697B (enExample) |
| MX (1) | MX384087B (enExample) |
| SG (1) | SG11201809714TA (enExample) |
| WO (1) | WO2017192543A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| KR102419524B1 (ko) | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| US10899738B2 (en) | 2016-05-02 | 2021-01-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| ES2872003T3 (es) | 2016-09-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Inhibidores espirobicíclicos de la interacción de menina-MLL |
| CN109715634B (zh) | 2016-09-14 | 2022-09-27 | 詹森药业有限公司 | Menin-mll相互作用的稠合二环抑制剂 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| KR102513564B1 (ko) | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| KR20190133224A (ko) * | 2017-03-31 | 2019-12-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 공유 메닌 억제제로서의 피페리딘 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| TW202003465A (zh) * | 2018-03-30 | 2020-01-16 | 美國密西根州立大學 | 作為共價menin抑制劑之六氫吡啶化合物 |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| JP2022502409A (ja) * | 2018-10-03 | 2022-01-11 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 低分子メニン阻害剤 |
| AU2019417833B2 (en) * | 2018-12-31 | 2024-11-07 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
| EP3906029A4 (en) | 2018-12-31 | 2022-09-21 | Biomea Fusion, LLC | MENIN-MLL INTERACTION INHIBITORS |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物 |
| MX2022007652A (es) | 2019-12-19 | 2022-09-23 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal. |
| TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| MX2023013174A (es) | 2021-05-08 | 2023-11-30 | Janssen Pharmaceutica Nv | Derivados espiro sustituidos. |
| JP2024518425A (ja) | 2021-05-08 | 2024-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換スピロ誘導体 |
| KR20240006625A (ko) * | 2021-05-12 | 2024-01-15 | 신닥스 파마슈티컬스, 인크. | 암 치료를 위한 조합물 |
| AU2022286467A1 (en) | 2021-06-01 | 2024-01-25 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES |
| BR112023025436A2 (pt) | 2021-06-03 | 2024-02-27 | Janssen Pharmaceutica Nv | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas |
| JP2024525145A (ja) | 2021-06-17 | 2024-07-10 | ヤンセン ファーマシューティカ エヌ．ベー． | がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩 |
| JP2024531170A (ja) | 2021-08-11 | 2024-08-29 | バイオメア フュージョン，インコーポレイテッド | 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤 |
| JP2024534014A (ja) | 2021-08-20 | 2024-09-18 | バイオメア フュージョン，インコーポレイテッド | 癌の処置のための不可逆的メニン－ＭＬＬ阻害剤、Ｎ－［４－［４－（４－モルホリニル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－イル］フェニル］－４－［［３（Ｒ）－［（１－オキソ－２－プロペン－１－イル）アミノ］－１－ピペリジニル］メチル］－２－ピリジンカルボキサミドの結晶形態 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| EP4525873A1 (en) * | 2022-05-17 | 2025-03-26 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| TW202430528A (zh) | 2023-01-18 | 2024-08-01 | 美商拜歐米富士恩股份有限公司 | Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑 |
| CN120987784A (zh) * | 2025-10-23 | 2025-11-21 | 辽宁鸿港化工有限公司 | 一种对甲氧基苄胺及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| AU7450898A (en) | 1997-05-28 | 1998-12-30 | Tokyo Tanabe Company Limited | Indole compounds |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| CA2773131C (en) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| US8946197B2 (en) | 2009-11-16 | 2015-02-03 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| IN2013MN02014A (enExample) | 2011-05-09 | 2015-06-12 | Forma Tm Llc | |
| BR112015022602A2 (pt) | 2013-03-13 | 2017-07-18 | Univ Michigan Regents | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos |
| US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| WO2014200479A1 (en) | 2013-06-12 | 2014-12-18 | The Regents Of The University Of Michigan | Menin-mll inhibitors and methods of use thereof |
| US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| RU2018126774A (ru) | 2015-12-22 | 2020-01-23 | Витэ Фармасьютикалз, Инк. | Ингибиторы менин-mll взаимодействия |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| KR102419524B1 (ko) | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| US10899738B2 (en) | 2016-05-02 | 2021-01-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| KR20190133224A (ko) | 2017-03-31 | 2019-12-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 공유 메닌 억제제로서의 피페리딘 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| WO2020069027A1 (en) | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
-
2017
- 2017-05-02 US US16/098,147 patent/US10899738B2/en not_active Expired - Fee Related
- 2017-05-02 CA CA3022868A patent/CA3022868A1/en not_active Abandoned
- 2017-05-02 MX MX2018013433A patent/MX384087B/es unknown
- 2017-05-02 ES ES17722968T patent/ES2899936T3/es active Active
- 2017-05-02 KR KR1020187034933A patent/KR20190015275A/ko not_active Ceased
- 2017-05-02 AU AU2017259436A patent/AU2017259436B2/en not_active Ceased
- 2017-05-02 EP EP17722968.9A patent/EP3452461B1/en active Active
- 2017-05-02 WO PCT/US2017/030577 patent/WO2017192543A1/en not_active Ceased
- 2017-05-02 JP JP2018557418A patent/JP6991585B2/ja not_active Expired - Fee Related
- 2017-05-02 SG SG11201809714TA patent/SG11201809714TA/en unknown
- 2017-05-02 CN CN201780040586.6A patent/CN109415337B/zh not_active Expired - Fee Related
- 2017-05-02 BR BR112018072570A patent/BR112018072570A2/pt not_active IP Right Cessation
-
2018
- 2018-10-31 IL IL262697A patent/IL262697B/en active IP Right Grant
-
2020
- 2020-11-23 US US17/101,323 patent/US20210198237A1/en not_active Abandoned
-
2021
- 2021-03-02 IL IL281182A patent/IL281182A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514950A5 (enExample) | ||
| RU2468016C2 (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ | |
| WO2012007877A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| JP2019509354A5 (enExample) | ||
| WO2012004714A3 (en) | Benzene sulfonamides as inhibitors of voltage-gated sodium channels | |
| CN107635547B (zh) | 用于治疗和预防肿瘤的甲苯哒唑多形体 | |
| JP2017527577A5 (enExample) | ||
| RU2016149233A (ru) | 1-((3s,4r)-4-(3-фторфенил)-1-(2-метоксиэтил)пирролидин-3-ил)-3-(4-метил-3-(2-метилпиримидин-5-ил)-1-фенил-1н-пиразол-5-ил)мочевина в качестве ингибитора trka киназы | |
| US20090215835A1 (en) | Treatment of cancer with sorafenib | |
| JP2017510641A5 (enExample) | ||
| US20160184309A1 (en) | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS | |
| JP5903433B2 (ja) | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ | |
| NO20064120L (no) | 3-'4-heterocyklyl-1,2,3,-triazol-l-yll-N-aryl-benzamid er som inhibitorer av cytokinproduksjon for behandling av kroniske inflammatoriske sykdommer | |
| MA38175B1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| WO2012004706A3 (en) | Chemical compounds | |
| MX2009005398A (es) | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. | |
| MA32382B1 (fr) | DÉRIVÉS INDAZOLES à SUBSTITUTION PHÉNYL OU PYRIDINYLE | |
| TW200519104A (en) | Quinazoline derivatives | |
| CL2012000755A1 (es) | Compuestos especificos 2-(3-amino-1-(2,4-difluorofenil)-1h-1,2,4-triazol-5-il)-n-metil-4,5-dihidrobenzeno(b) tieno(2,3-d)oxepina-8-carboxamida, inhibidor de la ctividad de la quinasa p13; composicon farmaceutica que lo comprende; kit farmaceutico que incluye a la composicion, y su uso para el tratamiento o profilaxis del cancer. | |
| Mahale et al. | Biphenyl-4-carboxylic acid [2-(1 H-Indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья | |
| JP5345842B2 (ja) | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ | |
| KR20150067323A (ko) | 조합물 | |
| RU2014103250A (ru) | Комбинированная терапия |